These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 22244991)

  • 1. [Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy].
    Burgos A; de Álvaro C
    Enferm Infecc Microbiol Clin; 2012 Mar; 30(3):167-8; author reply 168-9. PubMed ID: 22244991
    [No Abstract]   [Full Text] [Related]  

  • 2. [Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy].
    Blasco AJ; Arribas JR; Clotet B; Domingo P; González-García J; López-Bernaldo JC; Llibre JM; Lozano F; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM
    Enferm Infecc Microbiol Clin; 2011 Dec; 29(10):721-30. PubMed ID: 22014894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].
    Blasco AJ; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; López JC; Llibre JM; Lozano F; Miró JM; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM;
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):283-93. PubMed ID: 22525829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Does the cost of the drugs influence the choice of antiretroviral treatment regimens?].
    Rivero A
    Enferm Infecc Microbiol Clin; 2011 Dec; 29(10):719-20. PubMed ID: 22079230
    [No Abstract]   [Full Text] [Related]  

  • 5. [Analysis of costs and cost-effectiveness of the preferred treatments by GESIDA/National plan for AIDS for initial antiretroviral therapy in 2012].
    Martín-Herrero JE; Parrondo-García J; Rodríguez-Alcántara F
    Enferm Infecc Microbiol Clin; 2012 Oct; 30(8):509-10; author reply 511-2. PubMed ID: 22824178
    [No Abstract]   [Full Text] [Related]  

  • 6. [Budget impact analysis of antiretroviral therapy. A reflection based on the GESIDA guidelines].
    Grupo de trabajo de la Cohorte VACH
    Gac Sanit; 2012; 26(6):541-6. PubMed ID: 22498716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost and cost-effectiveness analysis of the preferred treatment for initial antiretroviral therapy in HIV infected adults according to 2012 GESIDA/National AIDS Plan guidelines].
    Betegón L; Cotarelo M; Vendrell B
    Enferm Infecc Microbiol Clin; 2012 Oct; 30(8):508-9; author reply 511-2. PubMed ID: 22819541
    [No Abstract]   [Full Text] [Related]  

  • 8. Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
    Rivero A; Pérez-Molina JA; Blasco AJ; Arribas JR; Crespo M; Domingo P; Estrada V; Iribarren JA; Knobel H; Lázaro P; López-Aldeguer J; Lozano F; Moreno S; Palacios R; Pineda JA; Pulido F; Rubio R; de la Torre J; Tuset M; Gatell JM
    Enferm Infecc Microbiol Clin; 2017 Feb; 35(2):88-99. PubMed ID: 27459919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drugs for antiretroviral therapy. The costs of HAART].
    Jablonowski H
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():21. PubMed ID: 19024911
    [No Abstract]   [Full Text] [Related]  

  • 10. [Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013].
    Blasco AJ; Llibre JM; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; López JC; Lozano F; Miró JM; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM;
    Enferm Infecc Microbiol Clin; 2013 Nov; 31(9):568-78. PubMed ID: 23969276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Senegal cuts deal for low-cost drugs.
    IAPAC Mon; 2001 Jan; 7(1):4. PubMed ID: 11305274
    [No Abstract]   [Full Text] [Related]  

  • 12. [GlaxoSmithKline again lowers prices of drugs for HIV/AIDS and malaria].
    Krankenpfl J; 2002; 40(7-9):222-3. PubMed ID: 12514863
    [No Abstract]   [Full Text] [Related]  

  • 13. Uganda cuts AIDS drug deal.
    IAPAC Mon; 2001 Feb; 7(2):40. PubMed ID: 11302022
    [No Abstract]   [Full Text] [Related]  

  • 14. A remedy beyond lower cost drugs.
    Zuniga JM
    IAPAC Mon; 2001 Sep; 7(9):267. PubMed ID: 11708270
    [No Abstract]   [Full Text] [Related]  

  • 15. Exploring the costs of a limited public sector antiretroviral treatment programme in South Africa.
    Boulle A; Kenyon C; Skordis J; Wood R
    S Afr Med J; 2002 Oct; 92(10):811-7. PubMed ID: 12432807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Debate over cost of AIDS drugs in Africa: children remain the most vulnerable.
    Meier E
    Pediatr Nurs; 2001; 27(3):309-10. PubMed ID: 12964678
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.
    Walensky RP; Weinstein MC; Yazdanpanah Y; Losina E; Mercincavage LM; Touré S; Divi N; Anglaret X; Goldie SJ; Freedberg KA;
    AIDS; 2007 May; 21(8):973-82. PubMed ID: 17457091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
    Marseille E; Saba J; Muyingo S; Kahn JG
    AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutting the cost of South African antiretroviral therapy using newer, safer drugs.
    Venter WF; Kaiser B; Pillay Y; Conradie F; Gomez GB; Clayden P; Matsolo M; Amole C; Rutter L; Abdullah F; Abrams EJ; Casas CP; Barnhart M; Pillay A; Pozniak A; Hill A; Fairlie L; Boffito M; Moorhouse M; Chersich M; Serenata C; Quevedo J; Loots G
    S Afr Med J; 2016 Dec; 107(1):28-30. PubMed ID: 28112085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.